Last reviewed · How we verify
LY01005
LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival.
LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival. Used for Cancer (specific indication under investigation in phase 3 trials).
At a glance
| Generic name | LY01005 |
|---|---|
| Also known as | Goserelin Acetate Sustained-Release Microspheres for Injection |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
LY01005 is designed to inhibit key kinases or signaling molecules implicated in cancer cell growth and survival. The drug is being developed by Luye Pharma Group Ltd. and is currently in phase 3 clinical trials, though the precise molecular target and detailed mechanism require further clinical characterization.
Approved indications
- Cancer (specific indication under investigation in phase 3 trials)
Common side effects
Key clinical trials
- To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer (PHASE2)
- Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (PHASE3)
- Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (PHASE1)
- Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (PHASE3)
- A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY01005 CI brief — competitive landscape report
- LY01005 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI